
Pfizer PFE.N said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, as the drugmaker expects to be an "earnings growth" story over the next three years
Median PT of brokerages covering the stock is $28 - data compiled by LSEG
ENCOURAGING COMMENTARY
BMO Capital Markets ("outperform", PT: "$30") says outperformance this quarter (particularly on the cost side) positions Pfizer well for the rest of the year, derisking the company's forecast amid a tumultuous economic backdrop
Jefferies (PT:$32) says PFE reported an ok Q1, adding the company's oncology drugs will start to resonate with investors
Leerink Partners ("market perform") says the company had encouraging comments on tariffs, dividend and M&A
J.P.Morgan (PT:$30) believes stronger new launch performance and/or further progress on the drugs in development will be necessary to significantly change the current narrative on the stock, which the brokerage sees as more likely from 2026